Protocol Single compound
VIP
Vasoactive intestinal peptide
Endogenous neuropeptide referenced in VPAC receptor and neuroimmune research.
Compare side by side →Laboratory reference · in vitro research data
- Research vial sizes
- 5 mg · 10 mg
- Dosing data
- Not listed — reference entry covers vial concentration only.
- Storage
- Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Reconstitution concentrations
Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.
| Vial | BAC water | mg/mL | mg per 10 u |
|---|---|---|---|
| 5 mg | 1 mL | 5 | 0.5 |
| 5 mg | 2 mL | 2.5 | 0.25 |
| 5 mg | 3 mL | 1.67 | 0.167 |
| 10 mg | 1 mL | 10 | 1 |
| 10 mg | 2 mL | 5 | 0.5 |
| 10 mg | 3 mL | 3.33 | 0.333 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Syringe
Research dossier · published literature summary
01
Mechanism of action
Vasoactive intestinal peptide (VIP; aviptadil as a drug) is a 28-amino-acid neuropeptide acting on VPAC1/VPAC2 receptors, causing vasodilation and anti-inflammatory effects in lung and gut.
02
Observed research endpoints
- RCT in critical COVID-19 respiratory failure: the primary endpoint was not met, though survival from respiratory failure at day 60 was reported as improved.
- Inhaled VIP in pulmonary hypertension: a modest, short-lived drop in pulmonary vascular resistance without lowering systemic blood pressure.
03
Regulatory & safety context
- Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
- No drug-related serious adverse events were reported in the COVID-19 trial; inhaled VIP caused no side effects in the pulmonary hypertension study.
04
Citations
- Youssef JG, et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure. Crit Care Med. 2022;50(11):1545–1554.2022-11Randomized controlled trialRead paper ↗
- Leuchte HH, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008;32(5):1289–1294.2008-11Clinical studyRead paper ↗
Keep exploring
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
View productView COA
Supplier C
TBDPlaceholder — details coming soon
View productView COA